FAAH and irritable bowel syndrome: Inhibiting these endocannabinoid catabolic enzymes is of major therapeutic interest as FAAH inhibitors are suggested as therapeutic targets for a group of diseases related to endocannabinoid level deficiencies termed “Clinical Endocannabinoid Deficiency Syndrome,” which have implications for migraine, fibromyalgia, and irritable bowel syndrome (McPartland et al., 2014; Russo, 2016).